These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17679059)

  • 1. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.
    Lieu HD; Shryock JC; von Mering GO; Gordi T; Blackburn B; Olmsted AW; Belardinelli L; Kerensky RA
    J Nucl Cardiol; 2007 Jul; 14(4):514-20. PubMed ID: 17679059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics.
    Mekkaoui C; Jadbabaie F; Dione DP; Meoli DF; Purushothaman K; Belardinelli L; Sinusas AJ
    JACC Cardiovasc Imaging; 2009 Oct; 2(10):1198-208. PubMed ID: 19833310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regadenoson in the detection of coronary artery disease.
    Buhr C; Gössl M; Erbel R; Eggebrecht H
    Vasc Health Risk Manag; 2008; 4(2):337-40. PubMed ID: 18561509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of regadenoson for measurement of fractional flow reserve.
    Prasad A; Zareh M; Doherty R; Gopal A; Vora H; Somma K; Mehra A; Clavijo LC; Matthews RV; Shavelle DM
    Catheter Cardiovasc Interv; 2014 Feb; 83(3):369-74. PubMed ID: 23765847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist.
    Zhao G; Messina E; Xu X; Ochoa M; Sun HL; Leung K; Shryock J; Belardinelli L; Hintze TH
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):369-75. PubMed ID: 17577101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of coronary stenosis with myocardial contrast echocardiography using regadenoson, a selective adenosine A2A receptor agonist.
    Le DE; Bragadeesh T; Zhao Y; Wang YG; Zha D; Kaul S
    Eur Heart J Cardiovasc Imaging; 2012 Apr; 13(4):298-308. PubMed ID: 22067143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory.
    Stolker JM; Lim MJ; Shavelle DM; Morris DL; Angiolillo DJ; Guzman LA; Kennedy KF; Weber E; Zareh M; Neumayr RH; Zenni MM
    Cardiovasc Revasc Med; 2015; 16(5):266-71. PubMed ID: 26242981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily Caffeine Consumption Is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson.
    Posch MI; Kay MD; Harhash AA; Huang JJ; Krupinski EA; Abidov A; McMillan NA; Kuo PH
    J Nucl Med Technol; 2020 Mar; 48(1):73-76. PubMed ID: 31604901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET.
    Goudarzi B; Fukushima K; Bravo P; Merrill J; Bengel FM
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1908-16. PubMed ID: 21656246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regadenoson.
    Bengalorkar GM; Bhuvana K; Sarala N; Kumar TN
    J Postgrad Med; 2012; 58(2):140-6. PubMed ID: 22718059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regadenoson.
    Garnock-Jones KP; Curran MP
    Am J Cardiovasc Drugs; 2010; 10(1):65-71. PubMed ID: 20063904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging.
    Hendel RC; Bateman TM; Cerqueira MD; Iskandrian AE; Leppo JA; Blackburn B; Mahmarian JJ
    J Am Coll Cardiol; 2005 Dec; 46(11):2069-75. PubMed ID: 16325044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the A2a receptor agonist, regadenoson, in modulating hepatic artery flow in the porcine small-for-size liver graft.
    Zhu X; Shiba H; Fung JJ; Wang LF; Arakawa Y; Irefin S; Demetris AJ; Kelly DM
    J Surg Res; 2012 May; 174(1):e37-45. PubMed ID: 22225980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of global myocardial perfusion reserve using cardiovascular magnetic resonance of coronary sinus flow at 3 Tesla.
    Dandekar VK; Bauml MA; Ertel AW; Dickens C; Gonzalez RC; Farzaneh-Far A
    J Cardiovasc Magn Reson; 2014 Mar; 16(1):24. PubMed ID: 24674383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist.
    Hodgson JM; Dib N; Kern MJ; Bach RG; Barrett RJ
    Am J Cardiol; 2007 Jun; 99(11):1507-12. PubMed ID: 17531571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats.
    Dhalla AK; Wong MY; Wang WQ; Biaggioni I; Belardinelli L
    J Pharmacol Exp Ther; 2006 Feb; 316(2):695-702. PubMed ID: 16227469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenoson.
    Bhave NM; Freed BH; Yodwut C; Kolanczyk D; Dill K; Lang RM; Mor-Avi V; Patel AR
    J Cardiovasc Magn Reson; 2012 Dec; 14(1):89. PubMed ID: 23272658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.
    Cerqueira MD; Nguyen P; Staehr P; Underwood SR; Iskandrian AE;
    JACC Cardiovasc Imaging; 2008 May; 1(3):307-16. PubMed ID: 19356442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.